KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Regeneron Pharmaceuticals (REGN) Inventory (2016 - 2025)

Regeneron Pharmaceuticals has reported Inventory over the past 14 years, most recently at $3.2 billion for Q4 2025.

  • Quarterly results put Inventory at $3.2 billion for Q4 2025, up 3.68% from a year ago — trailing twelve months through Dec 2025 was $3.2 billion (up 3.68% YoY), and the annual figure for FY2025 was $3.2 billion, up 3.68%.
  • Inventory for Q4 2025 was $3.2 billion at Regeneron Pharmaceuticals, down from $3.3 billion in the prior quarter.
  • Over the last five years, Inventory for REGN hit a ceiling of $3.3 billion in Q3 2025 and a floor of $2.0 billion in Q4 2021.
  • Median Inventory over the past 5 years was $2.5 billion (2023), compared with a mean of $2.6 billion.
  • Biggest five-year swings in Inventory: soared 46.17% in 2021 and later dropped 8.0% in 2022.
  • Regeneron Pharmaceuticals' Inventory stood at $2.0 billion in 2021, then grew by 23.09% to $2.4 billion in 2022, then grew by 7.44% to $2.6 billion in 2023, then rose by 19.64% to $3.1 billion in 2024, then increased by 3.68% to $3.2 billion in 2025.
  • The last three reported values for Inventory were $3.2 billion (Q4 2025), $3.3 billion (Q3 2025), and $3.2 billion (Q2 2025) per Business Quant data.